Bone Marrow TransplantationTransplantation, HomologousGraft vs Host DiseaseBone MarrowBone Marrow CellsWhole-Body IrradiationLiver TransplantationTransplantation, AutologousLeukemiaHematopoietic Stem Cell TransplantationAnemia, AplasticTransplantation ConditioningTransplantation ChimeraBusulfanTissue DonorsGraft SurvivalImmunosuppressive AgentsKidney TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveBone and BonesHistocompatibility TestingGraft RejectionHistocompatibilityRecurrenceLeukocyte TransfusionCyclophosphamideRadiation ChimeraBone Marrow PurgingGraft vs Tumor EffectLeukemia, Myeloid, AcuteTreatment OutcomeTransplantation, IsogeneicPrecursor Cell Lymphoblastic Leukemia-LymphomaRemission InductionHematologic NeoplasmsGraft vs Host ReactionHematopoietic Stem CellsLymphocyte DepletionTime FactorsRetrospective StudiesHeart TransplantationHepatic Veno-Occlusive DiseaseCombined Modality TherapyMice, Inbred C57BLAcute DiseaseGraft vs Leukemia EffectLeukemia, MyeloidHematopoiesisLymphocyte TransfusionImmunosuppressionChimeraT-LymphocytesTransplantation ImmunologyMyelodysplastic SyndromesBone Marrow DiseasesNuclear FamilyCyclosporineSurvival AnalysisActuarial AnalysisHLA AntigensLymphoma, Non-HodgkinHematologic DiseasesSevere Combined ImmunodeficiencyCytomegalovirus InfectionsBone Marrow ExaminationMice, Inbred BALB CFatal OutcomeCytarabineStem Cell TransplantationBone RemodelingAntineoplastic Combined Chemotherapy ProtocolsSurvival RateBone Marrow NeoplasmsProspective StudiesFollow-Up StudiesPancytopeniaDisease-Free SurvivalLeukocyte CountSpleenGranulocyte Colony-Stimulating FactorColony-Forming Units AssayEtoposideLymphomaInfectionMultiple MyelomaFlow CytometryLung TransplantationMethotrexateLeukemia, Myelomonocytic, AcuteAntilymphocyte SerumAnemia, Refractory, with Excess of BlastsPrognosisCell DifferentiationBone DensityNeoplasm, ResidualCyclosporinsImmunophenotypingImmunocompromised HostThymus GlandCarmustine